gastric/gastric-oesophageal junction adenocarcinoma
Conditions
Interventions
Observational single-armd study:None
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient or their legal representative may provide written informed consent and understand and agree to follow the study requirements and treatment evaluation schedule. 2. Male or female patients aged over 70 years. 3. Advanced gastric/gastroesophageal junction adenocarcinoma with peritoneal metastasis/malignant ascites (with tumor cells in the ascites) confirmed by pathology or histology. 4. Life expectancy >= 8 weeks. 5. Relatively adequate organ reserve function. A. Blood routine: absolute neutrophil count >= 1.5×109/L, platelets >= 75×109/L, hemoglobin >= 80g/L. B. Prothrombin time <= 1.5×ULN, activated partial thromboplastin time <=1.5×ULN. C. Serum total bilirubin <=1.5×ULN. D. Alanine aminotransferase and aspartate aminotransferase <=2.5×ULN.
Exclusion criteria
Exclusion criteria: 1. Extensive abdominal adhesions 2. Uncontrolled abdominal infection 3. Complete ileus 4. Pregnant or lactating women 5. Patients with proven hypersensitivity to endostar or envolimab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Paracentesis free survival,PFS; | — |
Countries
China
Contacts
Public ContactHuxueqing
Beijing Hospital
Outcome results
None listed